Summary

Market Overview
The Asia Pacific Cancer Diagnostics Market was valued at USD 6.41 billion in 2024 and is projected to reach USD 9.30 billion by 2030, growing at a CAGR of 6.60% during the forecast period. With cancer emerging as a leading cause of mortality across the region, there is a concerted push from governments, healthcare providers, and private players to enhance diagnostic infrastructure and improve access to screening programs. A key growth driver is the increasing use of advanced molecular diagnostic techniques such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid biopsy. These tools are revolutionizing cancer detection by enabling early diagnosis, accurate tumor profiling, and personalized treatment strategies. However, despite this promising outlook, the market contends with challenges including limited access in rural and underserved regions, the high cost of cutting-edge technologies, and regulatory fragmentation. Overcoming these barriers is essential for equitable service delivery and sustainable market expansion.
Key Market Drivers
Growth in Healthcare Industry
Asia’s healthcare sector is anticipated to reach USD 5 trillion by 2030, contributing 40% to global industry growth, and playing a pivotal role in expanding cancer diagnostic capabilities in the region. Government initiatives and private investments have increased healthcare spending and modernized infrastructure, allowing medical institutions to adopt advanced diagnostic technologies. This progress supports broader implementation of cancer screening programs across various countries. Nations such as China, India, Japan, and Australia are witnessing a growing elderly population and a rise in cancer prevalence, fueling the need for accurate and timely diagnostic solutions. In 2020, the cancer incidence rate in Asia stood at 169.1 per 100,000 people, accounting for nearly half of the global cancer burden. The most commonly diagnosed cancers included lung (13.8%), breast (10.8%), and colorectal (10.6%). This elevated burden is pressuring healthcare systems to scale up diagnostic capacity and introduce innovations like in vitro diagnostics, molecular assays, and liquid biopsy techniques into routine medical practice.
Key Market Challenges
High Cost of Advanced Diagnostics
The adoption of high-precision diagnostic technologies in the Asia Pacific cancer diagnostics market is significantly constrained by their cost. Techniques like next-generation sequencing (NGS), liquid biopsies, and molecular imaging, though advanced, are associated with high operational and infrastructure costs, limiting their accessibility—especially in low- and middle-income countries. These technologies often necessitate specialized equipment, well-equipped laboratories, and skilled personnel, resulting in financial strain for many public healthcare institutions. This is particularly true in regions of Southeast Asia, South Asia, and the Pacific, where public resources are limited. Consequently, access to these state-of-the-art diagnostics remains largely confined to urban centers or patients who can afford premium care, thereby restricting the reach of these advanced services across the broader population.
Key Market Trends
Expansion of Multi-Omics and Integrated Biomarker Platforms
The cancer diagnostics landscape in Asia Pacific is rapidly evolving with the integration of multi-omics and biomarker-driven platforms. This transformation is powered by the application of artificial intelligence—particularly deep learning and machine learning algorithms—that extract actionable insights from complex datasets. These advancements are enabling the development of more targeted and effective diagnostics and therapies. The limitations of single-marker tests are becoming increasingly evident, leading to a shift toward comprehensive approaches that incorporate genomic, proteomic, metabolomic, and epigenomic data. This multi-dimensional analysis allows for earlier and more accurate cancer detection and supports the personalization of treatment strategies, reinforcing the role of precision medicine in oncology.
Key Market Players
• Thermo Fisher Scientific, Inc.
• GE Healthcare
• Abbott Laboratories, Inc.
• Becton, Dickinson, and Company
• F. Hoffmann-La Roche Ltd.
• Boehringer-Ingelheim International GmbH
Report Scope
In this report, the Asia Pacific Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Asia Pacific Cancer Diagnostics Market, By Type:
o Lab Testing
o Genetic Testing
o Imaging Testing
o Biomarkers Testing
o In Vitro Diagnostic Testing
o Biopsy
o Others
• Asia Pacific Cancer Diagnostics Market, By Application:
o Lung Cancer
o Breast Cancer
o Colorectal Cancer
o Prostate Cancer
o Kidney Cancer
o Skin Cancer
o Others
• Asia Pacific Cancer Diagnostics Market, By Country:
o China
o India
o Japan
o Australia
o South Korea
o Rest of Asia Pacific
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Asia Pacific Cancer Diagnostics Market.
Available Customizations:
Asia Pacific Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Impact of COVID-19 on Asia Pacific Cancer Diagnostics Market
5. Asia Pacific Cancer Diagnostics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy, Others)
5.2.2. By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin cancer, Others)
5.2.3. By Country
5.2.4. By Company (2024)
5.3. Market Map
6. Asia Pacific: Country Analysis
6.1. China Cancer Diagnostics Market Outlook
6.1.1. Market Size & Forecast
6.1.1.1. By Value
6.1.2. Market Share & Forecast
6.1.2.1. By Type
6.1.2.2. By Application
6.2. India Cancer Diagnostics Market Outlook
6.2.1. Market Size & Forecast
6.2.1.1. By Value
6.2.2. Market Share & Forecast
6.2.2.1. By Type
6.2.2.2. By Application
6.3. Japan Cancer Diagnostics Market Outlook
6.3.1. Market Size & Forecast
6.3.1.1. By Value
6.3.2. Market Share & Forecast
6.3.2.1. By Type
6.3.2.2. By Application
6.4. South Korea Cancer Diagnostics Market Outlook
6.4.1. Market Size & Forecast
6.4.1.1. By Value
6.4.2. Market Share & Forecast
6.4.2.1. By Type
6.4.2.2. By Application
6.5. Australia Cancer Diagnostics Market Outlook
6.5.1. Market Size & Forecast
6.5.1.1. By Value
6.5.2. Market Share & Forecast
6.5.2.1. By Type
6.5.2.2. By Application
7. Market Dynamics
7.1. Drivers
7.2. Challenges
8. Market Trends & Developments
8.1. Merger & Acquisition (If Any)
8.2. Product Launches (If Any)
8.3. Recent Developments
9. Disruptions : Conflicts, Pandemics and Trade Barriers
10. Asia Pacific Cancer Diagnostics Market: SWOT Analysis
11. Porters Five Forces Analysis
11.1. Competition in the Industry
11.2. Potential of New Entrants
11.3. Power of Suppliers
11.4. Power of Customers
11.5. Threat of Substitute Products
12. Competitive Landscape
12.1. Thermo Fisher Scientific, Inc.
12.1.1. Business Overview
12.1.2. Company Snapshot
12.1.3. Products & Services
12.1.4. Financials (As Reported)
12.1.5. Recent Developments
12.1.6. Key Personnel Details
12.1.7. SWOT Analysis
12.2. GE Healthcare
12.3. Abbott Laboratories, Inc.
12.4. Becton, Dickinson, and Company
12.5. F. Hoffmann-La Roche Ltd.
12.6. Boehringer-Ingelheim International GmbH
13. Strategic Recommendations
14. About Us & Disclaimer